Vickers, Mark A <br/><br/>
Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.  [electronic resource] 

 -  British journal of haematology  Nov 2014 
 - 402-10 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.13051  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Allografts<br/>Central Nervous System Neoplasms--therapy<br/>Child, Preschool<br/>Epstein-Barr Virus Infections--immunology<br/>Female<br/>HLA Antigens--analysis<br/>Herpesvirus 4, Human--immunology<br/>Histocompatibility Testing<br/>Humans<br/>Immunotherapy, Adoptive<br/>Infant<br/>Leiomyosarcoma--therapy<br/>Licensure<br/>Lung Neoplasms--therapy<br/>Lymphoproliferative Disorders--etiology<br/>Male<br/>Middle Aged<br/>New Zealand<br/>Postoperative Complications--immunology<br/>Remission Induction<br/>Sarcoma--therapy<br/>T-Cell Antigen Receptor Specificity<br/>T-Lymphocytes, Cytotoxic--immunology<br/>Tissue Banks--organization & administration<br/>Treatment Outcome<br/>Young Adult